Log in

Clovis Oncology Stock Price, Forecast & Analysis (NASDAQ:CLVS)

$6.38
+0.07 (+1.11 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$6.21
Now: $6.38
$6.58
50-Day Range
$3.00
MA: $3.90
$6.56
52-Week Range
$2.93
Now: $6.38
$32.05
Volume5.35 million shs
Average Volume8.84 million shs
Market Capitalization$349.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$95.39 million
Book Value($1.60) per share

Profitability

Net Income$-368,010,000.00
Net Margins-298.53%

Miscellaneous

EmployeesN/A
Market Cap$349.69 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.


Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the Zacks' consensus estimate of ($1.89) by $0.17. The biopharmaceutical company earned $37.60 million during the quarter, compared to the consensus estimate of $35.84 million. Clovis Oncology had a negative return on equity of 1,576.32% and a negative net margin of 298.53%. The company's quarterly revenue was up 65.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.71) EPS. View Clovis Oncology's Earnings History.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Clovis Oncology.

What price target have analysts set for CLVS?

14 brokers have issued 12 month price objectives for Clovis Oncology's stock. Their forecasts range from $4.00 to $36.00. On average, they anticipate Clovis Oncology's stock price to reach $20.73 in the next twelve months. This suggests a possible upside of 224.9% from the stock's current price. View Analyst Price Targets for Clovis Oncology.

What is the consensus analysts' recommendation for Clovis Oncology?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:
  • 1. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019)
  • 2. According to Zacks Investment Research, "Clovis reported encouraging first-quarter results wherein its earnings and sales beat estimates. Market share of Clovis’ sole marketed drug Rubraca in the ovarian cancer PARP inhibitor market improved during the first quarter. Approval in second-line maintenance setting for ovarian cancer irrespective of BRCA-mutation is a positive. Successful development of Rubraca in several ongoing studies targeting different types of ovarian cancer patients is likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several PARP inhibitors under development. Clovis’ shares have outperformed the industry so far this year." (5/13/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "Clovis’ 4Q report was as expected following the top-line pre-announcement at The J.P. Morgan Healthcare Conference. Importantly, all key Rubraca clinical trials remain on track with the next material data updates likely at ESMO in September. In the meantime, we expect investors to continue to focus on the strategic value of the company, particularly in the wake of the GSK/TSRO deal. We are also increasingly asked about CLVS’s cash outlook given an accelerating operating spend and a first round of converts due in 2021 (~$284M). While these questions are likely to persist, we anticipate they will be secondary to the company’s strategic potential." (2/27/2019)

Has Clovis Oncology been receiving favorable news coverage?

Media headlines about CLVS stock have trended extremely negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clovis Oncology earned a news impact score of -5.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Clovis Oncology.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Incyte (INCY), Micron Technology (MU), Celgene (CELG), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Alibaba Group (BABA) and bluebird bio (BLUE).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Gamco Investors INC. ET AL (0.68%), First Midwest Bank Trust Division (0.38%), Gabelli Funds LLC (0.27%), Creative Planning (0.20%), California Public Employees Retirement System (0.12%) and Janney Montgomery Scott LLC (0.12%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Creative Planning, Campbell & CO Investment Adviser LLC and Oppenheimer & Co. Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Paul Edward Gross. View Insider Buying and Selling for Clovis Oncology.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Gamco Investors INC. ET AL, Janney Montgomery Scott LLC, Moloney Securities Asset Management LLC, Gabelli Funds LLC, McAdam LLC and California Public Employees Retirement System. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $6.38.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $349.69 million and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis. View Additional Information About Clovis Oncology.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is http://www.clovisoncology.com/.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  515 (Vote Outperform)
Underperform Votes:  508 (Vote Underperform)
Total Votes:  1,023
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel